Yahoo Finance

Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis

Basel, April 17, 2024 – Novartis today announced data from the ALITHIOS open-label extension study showing sustained efficacy of first-line, continuous Kesimpta ® (ofatumumab) treatment for up to six ...
Healthline

Kesimpta and Cost: What You Need to Know

Kesimpta (ofatumumab) is a prescription drug used to treat certain kinds of multiple sclerosis (MS) and clinically isolated syndrome. Kesimpta’s cost may depend on factors such as your dosage and ...
WebMD

Managing Multiple Sclerosis With Kesimpta: What You Need to Know

Kesimpta is a medicine used to treat relapsing forms of multiple sclerosis (MS). Relapsing forms of MS include clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS ...
PharmaTimes

Novartis reveals five-year efficacy data for Kesimpta

Patients treated with Kesimpta experienced considerable decreases in relapse rates Patients treated with Kesimpta experienced considerable decreases in relapse rates Novartis has presented pivotal ...
pharmaphorum

NICE says yes to Novartis' multiple sclerosis therapy Kesimpta

Novartis has secured backing from NICE for its relapsing multiple sclerosis (RMS) therapy Kesimpta in the UK, just two weeks after the drug was approved by the national drugs regulator. The ...
Healthline

All About Kesimpta’s Dosage

Kesimpta (ofatumumab) is a prescription drug used to treat clinically isolated syndrome (CIS) and multiple sclerosis (MS) in adults. The drug comes as a liquid solution for injection under the skin.
Nasdaq

Novartis : Six-Year Study Reveals Benefits Of Kesimpta In Newly Diagnosed Relapsing MS Patients

(RTTNews) - Novartis AG (NVS) said that an analysis of treatment-naive people who were recently diagnosed with relapsing multiple sclerosis found that first-line use of Kesimpta for up to six years ...
Monthly Prescribing Reference

Kesimpta Approved for Relapsing Forms of Multiple Sclerosis

Kesimpta, a CD20-directed cytolytic monoclonal antibody, is the first B-cell therapy intended for patient self-administration. The Food and Drug Administration (FDA) has approved Kesimpta® (ofatumumab ...
Seeking Alpha

New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies

ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after ...
Business Insider

FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis

EAST HANOVER, N.J., Aug. 20, 2020 /PRNewswire/ -- Novartis today announced that the US Food and Drug Administration (FDA) has approved Kesimpta® (ofatumumab, formerly OMB157) as an injection for ...
Healio

Early initiation of Kesimpta associated with lower rates of disability worsening in MS

Please provide your email address to receive an email when new articles are posted on . 80% of study participants remained free of disability-worsening events at 6 months. Cumulative event rates for 6 ...